The Paradox of the Finished Warehouse

Across the first four posts of this series, I have argued for a deliberate order of operations: a research-ready cohort (Post 1), an intelligence architecture on top of it (Post 2), a governance layer that translates raw reality into computable form (Post 3), and a standard data set that serves as the calibrated instrument (Post 4). By that logic, our DACCA cohort — a 5,000+ case colorectal cancer registry in Sichuan, with 28,000+ source records, 346 features per patient, refreshed daily, and spanning 12 provinces — should be a finished product.

It is not. Because there is a paradox every clinical data builder eventually hits: the warehouse can be perfectly built and still asleep. Data that is clean, standard, and computable is necessary but not sufficient. Until it becomes an asset — valued, protected by intellectual property, and lawfully usable beyond the wall of the original institution — it remains a cost center, not a research engine. The missing final step is medical data elementization (医疗数据要素化).

What "Data Elementization" Actually Means

The term is fashionable and therefore slippery. Stripped of rhetoric, medical data elementization has three non-negotiable components:

• Assetization — the data is recognized and managed as a divisible, evaluable asset, not a by-product of documentation.

• Intellectual property protection — the structured schema, the standard, the derived models, and the curated cohort carry protectable rights.

• Compliant circulation — the data (or its value) can move across institutions under privacy-enhancing constraints, rather than being trapped in one EHR.

This maps onto what the international community now frames as FAIR data (Findable, Accessible, Interoperable, Reusable) plus a legal and economic layer the FAIR principles deliberately leave open. The European Health Data Space, national data-property-rights pilots, and data-trust models are all attempts to close that open layer. I will not pretend our center has solved it. But we have built a path from the surgeon's bench that I think is worth sharing — because it starts from clinical responsibility, not from monetization.

Our Path: Standard-First, Then Elementized

The through-line of this series is that we never started with AI or with commerce. We started with the instrument. Elementization is the same discipline, one level up.

1. The standard is the first asset. Before anything can be an asset, it must be definable. Our Value-Based Colorectal Cancer Standard Data Set (ISBN 978-7-5727-0816-9) — the first such CRC standard in our national context — is itself the seed asset: a codified, versioned specification that others can adopt, cite, and build on. We have carried this into formal standard-setting: leading one group standard, participating in one national medical data-set standard, and three local/industry standards. A standard is the "language" that makes data elementizable at all.

2. An assetization system, patented. We have filed an invention patent — "A colorectal cancer data-assetization governance system and assisted clinical decision method" (2026, Sichuan University) — that couples the governed data layer to a decision-support method as a single protected unit. The point is not the patent per se; it is the recognition that the governance logic, not just the records, is intellectual property.

3. Compliant circulation via privacy-enhancing computation. Moving data across centers without moving the patient is the hard problem. In a National Natural Science Foundation program we are building, with privacy-computing and federated-learning collaborators at UESTC, a "data stays, model moves" architecture — so that a multi-center model trains on distributed CRC cohorts without raw records leaving their institution. This is where our work meets the international frontier: federated learning and privacy-enhancing technologies (PETs) are now the accepted technical answer to cross-institutional clinical AI, and our elementization path is built on exactly that substrate.

4. Data as a protected right, not a free resource. As a certified Sichuan Provincial Data Intellectual-Property Counselor and a member of the Data Element Committee of the China Information Industry Association, I work at the junction where clinical curation meets IP law. The lesson from that junction is blunt: the cohort is not the hospital's property to sell, nor the vendor's resource to scrape — it is a fiduciary asset held for the patients who generated it. Elementization without that fiduciary frame is just extraction.

The Engineering and Ethical Fault Lines

Elementization is where the earlier posts' abstractions become uncomfortable in practice. Three fault lines deserve candor:

• Standardization versus compliance. The same impulse that wants every variable uniformly coded also wants every record linkable. Those pull against de-identification and consent. We resolve this by separating the schema (shareable, standardized) from the identifiable record (locked, access-controlled) — the standard travels; the patient does not.

• Consent and the longitudinal cohort. A 30-year follow-up cohort was consented under a different data regime than today's. Retrofitting elementization onto legacy consent is genuinely hard and must be solved by governance, not by hopeful paperwork.

• Synthetic and federated alternatives. Where raw circulation is unlawful or unethical, synthetic data and federated training are the frontier answers — and they only work because the underlying data was standardized and governed first (Posts 3–4). Elementization inherits the maturity of everything beneath it.

Why "From the Clinic" Elementization Is Different

There is a dominant narrative that medical data should be "unlocked" for industry. I distrust that framing when it starts from the balance sheet. Our path is inverted: it starts from the surgeon's responsibility to the individual patient, proceeds through rigorous standardization and governance, and only then asks how the accumulated asset can create value — for research, for downstream centers, for the next patient.

That inversion matters. A center that treats data as a fiduciary asset, not a monetizable exhaust, will standardize it properly, govern it honestly, and circulate it sparingly. A center that starts from monetization will do the opposite. The technology (federated learning, PETs, data trusts) is neutral; the starting point is not.

The Through-Line of the Series

Step back across all five posts:

Research-ready cohort (Post 1) → intelligence architecture (Post 2) → governance layer (Post 3) → standard data set (Post 4) → data elementization (Post 5).

Each step is a precondition for the next. Skip the cohort and AI hallucinates. Skip governance and the standard is unenforceable. Skip the standard and the data cannot travel. Skip elementization and the whole edifice remains a warehouse — impeccable, and asleep.

This is the frontier of the Medical Data Element Engineering Research Center I lead: not bigger models, but the full chain from bedside record to protected, computable, circulable asset — owned responsibly, shared compliantly, and returned to patient care.

What's Next

The series has traced the chain from data to decision. A natural next arc would go operational: how a multi-agent system (Post 2) actually runs day-to-day on an elementized cohort (Post 5) to change bedside behavior — the translational proof that the whole stack was built for. That is the work now underway in our center, and where I hope to report results rather than philosophy.

Selected Readings & Resources

1. Wang XD, et al. Value-Based Colorectal Cancer Standard Data Set [以价值医疗为导向的结直肠癌标准数据集]. ISBN 978-7-5727-0816-9. — the codified standard that seeds elementization.

1. Wang XD. A colorectal cancer data-assetization governance system and assisted clinical decision method (invention patent, filed 2026, Sichuan University). — coupling governance and decision support as protected IP.

1. For the international frame: the FAIR principles (Wilkinson et al., Scientific Data, 2016) and the European Health Data Space remain the reference coordinates for making clinical data both reusable and lawful.

Join the Conversation

I'd like to hear how others are approaching the final step:

• Does your institution treat the data standard itself as intellectual property, or only the models trained on it?

• For cross-institutional CRC AI: are you circulating data, synthesizing it, or federating the model? Which proved durable?

• If you lead a clinical cohort, who do you consider the fiduciary owner of the elementized asset — the hospital, the patient, or a trust?

Comment below or reach out directly. Data elementization is where colorectal cancer data science either becomes an asset or stays a warehouse.

The views expressed in this post are the author's own and do not represent the position of any affiliated institution.